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ABSTRACT
Surveillance of ventilator-associated pneumonia (VAP) has been the common outcome
measurement used for internal and external benchmarking for mechanically ventilated patients;
and although not a clinical definition, it is commonly used as an outcome measurement for
research studies. Criteria in the VAP definition include both subjective and objective
components, leading to questions of validity. In addition, recent legislation has mandated the
public reporting of healthcare-associated infections, including VAP, in many states. Infectious
disease experts have recently recommended monitoring a new outcome, ventilator-associated
events (VAE), that contain specific objective criteria. The Centers for Disease Prevention and
Control (CDC) have refined this definition and released a new VAE protocol and algorithm,
replacing the VAP surveillance definition, as a result. The VAE protocol assesses for ventilatorassociated conditions (VAC).
The primary aims of this study were to determine the incidence of VAC; and to assess
four predictors for VAC, including two VAP prevention strategies (use of the subglottic secretion
drainage endotracheal-tube [SSD-ETT]), and daily sedation vacation); and two patient-related
factors (alcohol withdrawal during mechanical ventilation, and history of COPD). In addition, the
incidence for VAE, using a new national algorithm was determined.
Using a retrospective study design, electronic medical records of 280 veterans were
reviewed to identify cases of VAC using the VAE algorithm. The setting was two intensive care
units (ICU) at a large Veterans Administration Healthcare System (VAHCS) from October 2009
to September 2011. In addition to demographic information, variables were collected to
determine if cases met event criteria (VAC, infection-related ventilator-associated complication
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[IVAC], and possible or probable VAP). Incidence rates were calculated for VAC and IVAC.
Comparative data between those with and without VAC were assessed with independent sample
T-test or non-parametric equivalents.
The study sample was predominantly male (97.1%), Caucasian (92.1%), non-Hispanic
(90.7%); with a mean (SD) age of 67.2 (10.4) years. Twenty patients met the VAC definition
resulting in a VAC incidence of 7.38 per 1000 ventilator days. There were no statistically
significant differences in demographics or disease characteristics found between the two groups
(patients with VAC and patients without VAC). Using logistic regression, the impact of the four
predictors for VAC was assessed. None of the four explanatory variables were predictive of the
occurrence of VAC. Secondary outcomes (e.g. mechanical ventilation days, ICU days, hospital
days, and mortality) of veterans with VAC were compared to veterans without VAC. Results
indicated that the VAC group was associated with a significantly longer duration of ICU stay,
longer mechanical ventilation period, more likely to have a tracheostomy, and had a higher
mortality during hospitalization.
Expanding mechanical ventilation quality performance measures to include VAE/VAC
provides a better representation of infectious and non-infectious ventilator-associated problems,
and provides more accurate morbidity and mortality in this high-risk ICU population. Further
research is necessary to explore patient characteristics and prevention strategies that impact the
development of all VAC.
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CHAPTER 1: INTRODUCTION
Surveillance of healthcare-associated infections (HAI) by the infection preventionist (IP)
remains a cornerstone of every acute care Infection Control Program.1,2 The IP must accurately
and timely identify HAIs in the intensive care unit (ICU) and rapidly recognize trends to apply
necessary interventions. In addition to infection control surveillance requirements for
accreditation, many states have passed legislation to publicly report HAI rates. The Centers for
Disease Control and Prevention (CDC) provides HAI definitions that are used by IPs nationally.3
Ventilator-associated pneumonia (VAP) is a device-associated HAI that is monitored in
the acute care setting, and is associated with a high morbidity and mortality.2,4,5 Thus, the
incidence of VAP has been used as an outcome measure for assessing complications of
mechanical ventilation in clinical practice for decades; and has expanded from an internal quality
assurance measure to external benchmarking. Unfortunately, the CDC VAP definition was never
intended to be used for external benchmarking; and controversy with the subjective components
impact reliability and accuracy of case identification.6,7 Recently, infectious disease experts
proposed that ventilator-associated complications rather than VAP, is a superior measure of
morbidity and clinical outcomes. Chapter 2 provides the surveillance overview and challenges
with outcome measurements in the mechanically-ventilated adult.
The CDC expanded and refined the objective criteria, and developed a protocol for
ventilator-associated events (VAE).8 Identification of ventilator-associated conditions (VAC)
assesses deterioration in respiratory status to include both infection-related ventilator-associated
complications (IVAC) and non-infectious conditions (i.e. atelectasis, pneumonia, pulmonary
embolism, pneumothorax, fluid overload, and barotrauma); all of which impact morbidity and
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outcomes. One large civilian study reported ventilator-associated complication incidence rate of
21.2 per 1000 ventilator days compared to a VAP rate of 8.8 per 1000 ventilator days.9 Further
research by CDC refined the respiratory deterioration criteria of the new VAE definition to the
current fraction of inspired oxygen (FiO2) and positive-end expired pressure (PEEP) criteria.10,11
No studies to date have identified the incidence of VAC or predictors of VAC in the veteran
population. Baseline data for comparison is only one civilian study in the U.S.
Study Purpose and Aims
The primary aim of this study was to determine the incidence of VAC in mechanicallyventilated veterans in the ICU; and to identify the predictors of VAC, including two VAP
prevention strategies (subglottic secretion drainage endotracheal tube [SSD-ETT] and daily
interruption of sedation [sedation vacation], and two patient-related factors (alcohol withdrawal
during mechanical ventilation and history of chronic obstructive pulmonary disease [COPD]).
Secondary aims included comparing outcomes (mechanical ventilation days, ICU days, hospital
days, and mortality) of veterans with VAC to those without VAC; and comparing VAC
incidence with the pre-reported VAP rate (obtained from Infection Control database).
The specific research questions were:
•

What is the incidence of VAC in mechanically-ventilated veterans in the ICU?

•

In mechanically-ventilated veterans identified with VAC, what is the incidence of
infectious VAC compared to non-infectious VAC?

•

Is the incidence of VAC in mechanically-ventilated veterans influenced, individually or
in combination, by a history of COPD, alcohol withdrawal, use of a SSD-ETT, and daily
sedation vacation?

2

Conceptual Model: Pathogenesis of VAE
Critical care patients that require mechanical ventilation are at risk of pulmonary
complications. Selection of variables to study was based on the Conceptual Model of the
Pathogenesis of VAE (Figure 1). This model was based on the pathogenesis of ventilator-related
infections and complications, and infection control strategies for prevention of VAP.2,5,8,12
Following insertion of an artificial airway (endotracheal tube [ETT]) to assist in
respiration, colonization of the naso/oralpharyngeal tract begins around and within the lumen of
this assistive respiratory device.12 Commonly there is pooling and subsequent leakage of
bacteria-laden secretions around the ETT cuff, that results in bacterial exposure to the lower
respiratory tract and host defenses.13 The normal airway and defense mechanisms are
compromised with an ETT that is necessary to support mechanical ventilation and sustain
respiratory parameters, resulting in colonization, potential ventilator-associated complications,
and other adverse events.2,14,15
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Figure 1: Conceptual Model of VAE

Impact of Prevention Strategies and Patient Factors on VAC
The Institute for Healthcare Improvement (IHI) recommends a set of ventilator
prevention strategies that are standard ICU practices: including: elevation of the head of the bed,
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peptic ulcer prophylaxis, deep venous thrombosis prophylaxis, oral care with chlorhexidine, and
the sedation vacation.5 The Veterans Administration Healthcare System (VAHCS) adopted
implementation of the IHI ventilator bundle, and adherence is monitored. Implementation of the
sedation vacation, which includes decreasing patient sedation until spontaneous ventilation
occurs, is often difficult due to a variety of medical reasons or contraindications, including
alcohol withdrawal.16-18 Alcohol abuse is a continued problem in the veteran population.19,20
During mechanical ventilation, patients require sedation to reduce or prevent agitation
that may cause additional airway trauma, ETT displacement, or accidental extubation. Daily
interruption of sedation is recommended to assess readiness to wean from mechanical
ventilation.5,21,22 Alcohol withdrawal maybe the primary reason for intubation, thus protecting
the airway, and mechanical ventilation is necessary during sedation to decrease agitation.
Sedation and alcohol withdrawal scales are frequently used to assess the amount of medication
necessary, and many facilities have implemented sedation protocols to facilitate a sedation
vacation or daily interruption of sedation.23 Although a daily sedation vacation is recommended,
practices vary depending on individual patient circumstances and there are no studies indicating
the impact of sedation vacation or alcohol withdrawal on the incidence of VAC.
The ETT provides a direct pathway for air exchange during mechanical ventilation and
for suctioning of lower respiratory tract secretions. The ETT can act as a conduit for
microorganisms resulting in airway colonization; as micro-aspiration of bacteria-laden secretions
that pool above the ETT cuff may result in a lower respiratory tract infection. While the ETT
cuff is inflated in the trachea, channels are created within the ETT cuff folds and increase the risk
for micro-aspiration of the pooled oral-pharyngeal secretions above the cuff. In research studies
using the SSD-ETT to provide continuous or intermittent removal of pooled secretions, study
5

results indicate improved patient outcomes and reduced lower respiratory tract infections,
specifically VAP.24-26 The SSD-ETT is available and many patients are intubated with this tube;
however many ICU patients are intubated with a standard ETT during surgery or are transferred
intubated from another facility. It is recommended that a SSD-ETT be used for mechanical
ventilation to prevent VAP26, but there are no studies indicating the success or failure of this
recommendation on the incidence of VAC.
Research indicates that weaning from mechanical ventilation can be a problem in patients
with COPD; and patients with COPD have been found to be at high risk for VAP, have increased
mechanical ventilation days, and higher mortality.27-28 The incidence of COPD in the veteran
population is high in a recent study, 39% of veterans were active smokers, and the odds of
having COPD were 3.18 times greater in smokers than non-smokers. 29 In the recent civilian
study, 31% of patients identified with ventilator-associated complications had COPD.9
Ventilator-Associated Complications
The conceptual model of VAE (Figure 1) was used to guide the research study to
determine the incidence of VAC and to identify the predictors of VAC. Following Institutional
Review Board approval, a retrospective study of 280 mechanically-ventilated veterans from two
ICUs in a large VAHCS setting was performed. Data were extracted from the electronic medical
record. Data and results of the study are discussed in Chapter 3.
By understanding the pathogenesis of VAE, this model can be used to guide research in
VAC incidence; and determine the impact of prevention strategies on the development of VAC,
IVAC, and VAP. Issues in retrospective assessment of VAE (e.g. mechanical ventilation
respiratory parameters, sedation vacation, and SSD-ETT) that could impact results are discussed
in Chapter 4.
6
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CHAPTER 2: OUTCOME MEASUREMENTS FOR COMPLICATIONS OF
MECHANICAL VENTILATION
Summary Abstract
The incidence of ventilator-associated pneumonia (VAP) has been a common outcome
measure used for assessing complications of mechanical ventilation in clinical practice and
research, and for internal and external benchmarking. Although the Centers for Disease Control
and Prevention (CDC) VAP definition is commonly used for surveillance, controversy with
subjective components impact reliability and accuracy. Recently, researchers studied several
combinations of surveillance criteria, and the CDC announced expanding VAP surveillance to
capture ventilator-associated events (VAE) based on respiratory deterioration criteria.
Background: VAP Surveillance
Medical treatment in an intensive care unit (ICU) for many critical illnesses and injuries
require the assistance of an artificial airway (endotracheal tube [ETT]) and mechanical
ventilation for survival. Intubation and mechanical ventilation are often associated with lifethreatening pulmonary complications and infections while the airway is compromised.1
Strategies are aimed at providing supportive care to prevent respiratory tract infections and other
complications. Infection control surveillance includes VAP as an outcome measurement, using
the widely used CDC VAP definition.2 Multidisciplinary studies frequently use the presence of
VAP as an indicator of the success or failure of nursing, medical, or pharmaceutical interventions
in the mechanically-ventilated adult. In addition, quality improvement programs based on
evidence-based prevention strategies, termed the ventilator bundle, have become a standard ICU
practice with VAP used as the indicator of success.3,4
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In 2011, the National Healthcare Safety Network (NHSN) reported that VAP ICU
incidence ranged from mean 1.0 -1.1 (medical ICU, medical major teaching ICU) to 2.0-2.4
(surgical ICU, surgical major teaching ICU) cases per 1000 ventilator days.5 Rates have
decreased compared to a previous NHSN report, and other reports estimated VAP incidence
from 1 to 4 cases per 1,000 ventilator days.1,6 As a serious healthcare-associated infection
(HAI), VAP impacts hospital care and length of stay and is associated with a longer period of
mechanical ventilation, ICU stay, and hospitalization. In addition, VAP is associated with an
increase in morbidity and mortality with reported attributable cost up to $28,508.1,7 The
economic impact of VAP was reported to have a median hospital cost of $35,480 greater than
matched controls in one study.8
Over the past several years, there has been an increased public interest in VAP outcomes
due to changes in HAI reimbursement regulations and legislature changes in public reporting.
Although public reporting has promoted interest in VAP prevention and outcomes, it also creates
pressure for the Infection Preventionists (IP) to strictly interpret the definition criteria which may
result in artificially decreasing VAP rates.9 Previous challenges with VAP interpretation and
subsequent rates were only experienced with internal committees, but now accountability has
expanded to external comparison, public reporting, and hospital revenue.10-12 The addition of
external reporting has forced experts to re-evaluate the VAP definition to standardize criteria to
ensure reliability and validity.13,14
The VAP definition contains subjective criteria resulting in a high range of inter-observer
variability.1,15,16 Diagnostic components used to distinguish and define VAP include pulmonary
criteria, systemic signs and symptoms of infection, and radiographic criteria; but components are
without precise criteria for interpretation.1,2 Microbiologic criteria are also controversial due to
12

the various techniques in specimen collection and processing, with reports of poor sensitivity and
specificity of specimens.17,18 Although these problems with the VAP definition are well known,
VAP incidence based on this definition continues to be used as a performance indicator for
hospitals to compare outcomes.1 Thus, using the current CDC VAP definition to identify cases
impacts the validity of any reported VAP incidence rates used both internally and externally as
quality benchmarks, and do not accurately reflect quality of care.19,20
Process to Improve Outcome Measurements
To circumvent the problems with the CDC VAP definition, researchers began using other
end-points to assess the success of interventions on mechanical ventilation outcomes. In an
attempt to improve surveillance, a modified VAP definition using specific measurable criteria in
an algorithmic approach was used by researchers to evaluate electronic data.21 The modified
VAP definition kept the basic structure of the VAP definition in that two pulmonary criteria, one
systemic criterion, and one radiographic criterion would need to be fulfilled. Instead of the
subjective criteria in the CDC VAP definition, the modified VAP definition included objective
and measurable criteria that could be retrieved from the electronic record (Table 1). For example,
specific criteria for a sustained increase in fraction of inspired oxygen (FiO2) or positive-end
expiratory pressure (PEEP) was used instead of the subjective interpretation of a worsening gas
exchange (CDC VAP definition). A modified VAP incidence rate of 8.3 per 1000 ventilator
days was found, and a 100% positive predictive value when comparing cases to the traditional
CDC VAP definition criteria.21
Further research on using ventilator-associated complications as a quality indicator was
undertaken, and criteria was based on a change in respiratory demand reflected in the need for an
increase in ventilator settings (FiO2 or PEEP) following a two day period of stability. In a
13

multicenter retrospective study, the ventilator-associated complications definition was used to
review data from 600 mechanically ventilated adults in which this incidence was compared to
VAP; and other secondary outcome measurements were compared for the two outcomes.22 A
VAP incidence rate of 8.8 per 1000 ventilator days was found compared to a ventilatorassociated complication incidence of 21.2 per 1000 ventilator days. The ventilator-associated
complication diagnostic criteria used an objective quantitative approach in assessing changes in
ventilator settings in determining a change in oxygenation requirements compared to the
traditional CDC VAP definition. Top etiologies of ventilator-associated complications reported
included: any pulmonary complication (59%), pneumonia (23%), adult respiratory distress
syndrome (16%), pulmonary edema (18%), and atelectasis (11%).22 Thus, ventilator-associated
complications encompassed both infectious and non-infectious etiologies, and emerged as a
possible superior clinical indicator of mortality compared to VAP.
The CDC began a process of testing a revised VAP definition for adults on mechanical
ventilation based on this research.21,23-25 Initial research and plans to quantify criteria using a
streamlined VAP [s-VAP] surveillance definition were presented at national meetings.24
Specific measurable criteria included adults being mechanically-ventilated for four or more days
which included at least two days of stability. The two days of stability were followed by an
indicator of respiratory deterioration (minimum daily value of FiO2 increased at least 0.15 [15
points] or minimum daily PEEP value increased at or above 2 cm H2O, with either FiO2 or PEEP
remaining at the increased level for two or more calendar days) and indicators of inflammation
(fever, leukopenia/leukocytosis, and quantitatively-defined purulent sputum). Reported results
indicated that using the s-VAP definition with two indicators of inflammation generated a more
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reasonable event rate (7 per 1000 ventilator days) compared to only using one indicator (10 per
1000 ventilator days).
Table 1: Comparison of Assessment Criteria for VAP, Modified VAP, s-VAP, and Ventilator-Associated

Complication
Definition

Pulmonary Criteria

Systemic Criteria

Radiographic Criteria

Ventilator-Associated
Pneumonia (VAP)2

Any 2 of the following:
-New onset of purulent sputum
(≥25 neutrophils and ≤10
squamous epithelial cells) or
change in character of sputum or
increased respiratory secretions
or increased suctioning
requirements
-New onset or worsening cough,
dyspnea, or tachypnea
-Rales or bronchial breath
sounds
-Worsening gas exchange (e.g.
O2 desaturations [eg.PaO2/FiO2
≤240]), increased oxygen
requirements, or increased
ventilator demand

At least 1 of the following:
-Fever (>38°C or
>100.4°F) w/no other
cause;
-Leukopenia (<4000
WBC/mm3) or
leukocytosis (≥12,000
WBC/mm3);
-Adults ≥ 70 years old,
altered mental status with
no other recognized cause.

Two or more serial
chest radiographs w/at
least 1 of the following:
-New or progressive
and persistent infiltrate
-Consolidation
-Cavitation
Note: In patients
without underlying
pulmonary or cardiac
disease, one definitive
chest radiograph is
acceptable.

Modified VAP21

Both of the following:
-Sustained rise in ventilator FiO2
>15 mm Hg over 48 hours
OR sustained rise in ventilator
PEEP by >5cm H20 over 48
hours OR simultaneous rise in
FiO2 >10mm Hg AND rise in
PEEP > 2.5 cm H20 sustained
over 48 hours.
-Gram stain of respiratory
secretion sample with > 25
neutrophils per high power field
within past 72 hours

Any 1 of the following:
-Fever >38°C (100.4°F)
within past 24 hours;
-Leukopenia (<4000
WBC/mm3) or
leukocytosis (≥12,000
WBC/mm3) within past 24
hours

Any 1 of the following:
-Opacity, infiltrate, or
consolidation that
appears, evolves, or
persists over > 72 hours
-Cavitation

Modified VAP [sVAP]24 (CDC 1st
Draft)

Mechanically ventilated >3 days;
- 2 calendar day period of
stability or improvement on the
ventilator
- Sustained (>2 calendar days)
increase FiO >15 points OR

Any 1 of the following
inflammatory signs
-Fever ( >38°C or < 36°C)

Not applicable

2

PEEP increase > 2 cm H2O.
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- White Blood Cell Count
(>12,000 WBC/mm3 or
<4000 WBC/mm3)
-Quantitatively-defined
purulent sputum (≥ 25
neutrophils and ≤ 10
squamous epithelial cells
per low power field)

Definition

Pulmonary Criteria

Systemic Criteria

Ventilator-Associated
Complication22

Patients must have:
-Minimum of 2 days of stable or
decreasing daily minimum PEEP
or FiO2.
Followed by:
-Increase in the daily minimum
PEEP by 2.5cm H20 sustained
for > 2 days OR increase in daily
minimum FiO2 by >15 points
sustained for > 2 days.

Not applicable

Radiographic Criteria
Not applicable

CDC researchers further evaluated 32 different possible objective definitions that were
based on various combinations of indicators of respiratory deterioration and infection.26
Different indicators of respiratory deterioration based on ventilator settings that were evaluated
included: increase in the daily minimum PEEP by at least 2 cm H2O or the FiO2 by 15 points
sustained for two or more calendar days, increase in the daily minimum PEEP by at least 3 cm
H2O or the FiO2 by 20 points sustained for two or more calendar days, and increase in the daily
minimum PEEP by at least 5 cm H2O or the FiO2 by 20 points sustained for two or more
calendar days; plus various indicators of infection (abnormal temperature, white cell count,
purulent secretions [indicated by gram stain], and culture). In this retrospective study, results
indicated that increased hospital mortality was significantly associated with the definitions that
required respiratory deterioration criteria.26 Defining respiratory deterioration with specific
parameters of a sustained increase in FiO2 or PEEP, following a two calendar day period of
stability, also predicted an increase in ventilator days and hospital days, although adding
systemic infection thresholds did not impact outcomes.26
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New VAE Surveillance Definition
This evidence-based process to quantify and validate the VAP definition has resulted in a
new surveillance definition. In January 2013, the CDC introduced the VAE protocol, and
indicated that VAE will replace the widely used VAP definition.27 The VAE protocol contains
three tiers: the first tier is determining ventilator-associated condition (VAC) that is based on
respiratory deterioration (FiO2 or PEEP); and if VAC is met, then the second tier is assessed for
the occurrence of an infection-related ventilator-associated complication (IVAC) based on
inflammatory signs; if IVAC is met, then the third tier based on microbiology data is assessed for
a possible or probable VAP (Figure 2).
CDC experts are already recommending that public reporting and external comparison
include VAC and IVAC only, with possible and probable VAP being used for internal quality
improvement purposes.27 The new VAE algorithm contains specific criteria promising for data
mining and electronic data extraction for case identification. Expanding the VAE definition to
assess for all potential avoidable ventilator occurrences will enable clinicians to begin
recognizing trends in other conditions and potential patient safety issues, implement necessary
interventions, and improve patient outcomes. Thus, the long term goal to minimize variability
across observers with a standard definition and provide a reliable measure with clinical relevance
may be achieved; and by using specific measurable objective criteria, data-mining technology
using precise algorithms can facilitate immediate case finding.
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Figure 2: VAE Surveillance Algorithm; from: http://www.cdc.gov/nhsn/acute-care-hospital/vae/
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Summary
Expanding and improving mechanical ventilation quality performance measures to VAE
will provide a better representation of clinical improvements and challenges, improve data
validity, provide a better benchmark for comparison, and eliminate the present confusion with
the current VAP definition. The IP will be able to consistently and accurately identify cases with
less conflict and analyze data for common factors to reduce the incidence of HAI; and thus
reduce morbidity and save healthcare dollars. Using VAE (VAC and IVAC) as an outcome
indicator will provide a standard and valid measurement for research and external rate
comparison.
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CHAPTER 3: FINDINGS
Abstract
Ventilator-associated pneumonia (VAP) has been the traditional outcome measurement
for critically-ill patients on mechanical ventilation. Recently, the Centers for Disease Control
and Prevention (CDC) updated and expanded the VAP surveillance definition to include all
ventilator-associated events (VAE), specifically addressing ventilator-associated conditions
(VAC) that can be either non-infectious related conditions or infectious ventilator-associated
complications (IVAC). Further internal quality measurement criteria to identify if an IVAC is a
possible or probable VAP are included in the algorithm. The primary aims of this retrospective
study was to determine the incidence of VAC; and to assess four predictors for VAC, including
two VAP prevention strategies (use of the subglottic secretion drainage endotracheal-tube [SSDETT], and daily sedation vacation), and two patient-related factors (alcohol withdrawal during
mechanical ventilation, and history of chronic obstructive pulmonary disease [COPD]).
Using a retrospective study design, electronic medical records of 280 subjects were
reviewed using the CDC VAE algorithm. The setting was two intensive care units (ICU) in a
Veterans Administration Healthcare System (VAHCS). Medical records of those who met
inclusion criteria (orally intubated, mechanically-ventilated for a minimum period of two
calendar days) from October 2009 to September 2011 were reviewed. In addition to
demographic information, variables were collected to determine if cases met VAC event criteria
to determine an incidence rate based on 1000 ventilator days. Comparative data between those
with and without VAC were assessed with independent sample T-test or non-parametric
equivalents. Using logistic regression, the impact of the four predictors for VAC was assessed.
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Secondary outcomes (mechanical ventilation days, ICU days, hospital days, and mortality) of
veterans with VAC were compared to veterans without VAC.
Twenty patients met the VAC definition resulting in a VAC incidence of 7.38 per 1000
ventilator days. No statistically significant differences in demographics or disease characteristics
were found between the two groups (patients with VAC and without VAC). Logistic regression
was performed on occurrence of VAC and the four predictors. Results indicated that these four
explanatory variables were not predictive of the occurrence of VAC. Secondary outcomes
indicated that the VAC group was significantly associated with a longer duration of ICU stay,
longer mechanical ventilation period, more likely to have a tracheostomy, and had a higher
likelihood for mortality during hospitalization.
Expanding mechanical ventilation quality performance measures to include VAE/VAC
provides a better representation of ventilator-associated improvements and complications; and
provides more accurate morbidity and mortality in this high-risk ICU population. Further
research is necessary to explore patient characteristics and nursing interventions that impact the
development of all VAE.
Introduction and Background
Ventilator-associated pneumonia incidence rates have been used for decades as an
outcome measurement in mechanically-ventilated patients, although experts acknowledge that
VAP surveillance has high inter-observer variability which impacts credibility for external
comparison.1,2 Expanding surveillance from VAP to include other complications has emerged as
a superior indicator of mortality.3,4 The CDC recently announced in January 2013, that a VAE
protocol would replace the VAP surveillance definition in adults. Within the VAE algorithm
four possible events can be determined for surveillance purposes: 1) VAC, 2) IVAC, 3) possible
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pneumonia, and 4) probable pneumonia. The goal of this research-based VAE algorithm was to
significantly expand, improve, and standardize surveillance for ventilator-associated
infections.5,6
A retrospective, descriptive study was designed to apply the new CDC VAE algorithm to
critically-ill, mechanically-ventilated veterans. The primary aims were 1) to determine the
incidence of VAC; and 2) to assess the predictive ability of two VAP prevention strategies (SSDETT, and daily sedation vacation), and two patient-related factors (alcohol withdrawal during
mechanical ventilation, and history of COPD) on VAC. Secondary outcomes (mechanical
ventilation days, ICU days, hospital days, and mortality) of veterans with VAC were compared
to veterans without VAC. In addition, the VAC incidence rate was compared with the prereported VAP rate (obtained from Infection Control database), and the etiology of VAC
incidence was grouped into infectious and non-infectious complications for comparison.
The Institute for Healthcare Improvement (IHI) recommends a set of ICU ventilator
prevention strategies that are expected practices: elevation of the head of the bed, peptic ulcer
prophylaxis, deep venous thrombosis prophylaxis, oral care with chlorhexidine, and the sedation
vacation.7,8 The Veteran’s Health Administration (VHA) system has adopted implementation of
the ventilator bundle, and compliance was monitored.
The first predictor reviewed for this study was the SSD-ETT, which was available at the
study site for use; however, many ICU patients are intubated with a traditional endotracheal
(ETT) either during surgery or transferred into the ICU intubated from another facility.9,10 This
variation in intubation practices provided an opportunity to assess the effectiveness of the SSDETT device in preventing VAC. The second predicator was the sedation vacation, which
included decreasing patient sedation until spontaneous ventilation occurred, which may be
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difficult to achieve daily due to a variety of medical reasons or contraindications, including
alcohol withdrawal. The third and fourth predictors in this study were based on known high risk
patient-related factors (alcohol withdrawal and COPD). Soldiers are known to have a higher
than average consumption of alcohol and cigarettes (with smoking known as a precursor to
development of COPD). These behaviors continue after retirement and discharge and continue
to be seen at a higher rate in the veteran population, and influence morbidity.11-13 This is the first
study known to assess the impact of these four factors on VAC.
Methods
Setting and Sample
The setting was a large Veteran Administration Healthcare System (VAHCS) in the
Southeastern United States. Subjects received mechanical ventilation in either the surgical or
medical ICU between October 1, 2009 and September 30, 2011. The IHI ventilator bundle was
implemented in 2007, with chlorhexidine oral care added in 2010. The SSD-ETT was
implemented in the ICUs and emergency intubation trays in 2006 (HiLo®Evac ETT). During the
spring of 2010 the Mallinckrodt™ TaperGuard™ Evac ETT replaced the HiLo®Evac SSD-ETT.14
The SSD-ETT was not implemented in the operative area until 2009 when anesthesia providers
were encouraged to consider using the SSD-ETT for patients that may require mechanical
ventilation post-operatively. The SSD-ETT was not used on every patient, and the sedation
vacation was not often done; thus, providing an opportunity to compare the effectiveness of these
interventions on the incidence of VAC in this veteran population. The time period selected for
the study was after the implementation of the IHI bundle and SSD-ETT in this VAHCS ICU
population.
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The sample consisted of adult veterans (≥18 years), orally intubated with an ETT or SSDETT, who required mechanical ventilation for at least two calendar days. Exclusion criteria
included any non-veteran, veterans under age 18, admission with existing tracheostomy, and
aspiration documented at time of admission. Subjects were identified from historic infection
control data (received from the Respiratory Therapy department that included patients on
mechanical ventilation and number of mechanical ventilation days). All patients on mechanical
ventilation during the 24 months were screened to verify inclusion criteria, resulting in 280
subjects.
Respective institutional review boards at the VAHCS and the university approved the
study, along with waiver of informed consent. All subjects were assigned a random number after
meeting inclusion criteria. Data was de-identified during data extraction, therefore only deidentified data were available for analysis.
The method for determining a sample size for the logistic model with a binary covariate
was used for the sample size estimation, with data from 300 subjects estimated a-priori to satisfy
the inclusion criteria for analysis. This sample size would ensure a Type I error 0.05 and a
power of 80% for the primary analysis.15 Sample size for the logistic regression model with a
binary covariate X is determined by B, proportion of samples at X =1; VAC event rate p1 at X=1,
and VAC event rate p2 at X=0. Table 2 provides sample sizes for various values of p1, p2 and B.
Table 2: Sample Size for Logistic Regression with VAC Event Rate p1 at X=1, VAC Event Rate p2 at X=0
B=20%
B=45%
B=55%
B=80%
p1 = 0.8
p1 = 0.7
p1 = 0.6
p1 = 0.5
p2=0.6
31
71
94
262
p2=0.5
42
81
106
294
p2=0.4
50
86
110
300
p2=0.3
54
83
105
282
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All analyses of predictive VAC risk factors were conducted with a 2-tailed test and at the
0.05 significance level. If one predictive factor was missing the whole record for a patient was
excluded from analysis without imputation; there were no missing factors recorded and all
subjects were included in data analysis. During the approved study time period, only 280
mechanically ventilated patients met inclusion criteria.
Measures
Demographic and Medical History
Demographic data and medical history were extracted from the electronic medical record
(Appendix A). Various demographic and morbidity/mortality data were collected (e.g. age,
gender, ethnicity, body mass index [BMI], admitting diagnosis, ICU admission diagnosis, acuity
score [Charlson score], surgical procedures related to ICU admission, intubation circumstances
[place, type of ETT], and occurrence of mortality).
The CDC VAE algorithm (Figure 3) was used for every patient to determine the
occurrence of VAC, IVAC, possible pneumonia, and probable pneumonia and collect the
necessary variables (Appendix A).
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Figure 3: VAE Surveillance Algorithm; from: http://www.cdc.gov/nhsn/acute-care-hospital/vae/
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Procedures
Demographic, Medical, and Hospitalization History
Each medical record was reviewed for necessary data. Dates of care were de-identified
and recorded numerically during data collection: hospital length of stay (calculated from dates of
hospital admission and discharge), ICU length of stay (calculated from dates of ICU admission
and discharge), number of days mechanically ventilated (calculated from dates of intubation and
extubation), and occurrence and timing of tracheostomy (intubation date and tracheostomy date,
if applicable). Although some patients had re-admissions to the ICU, only the ICU length of stay
related to the first ventilator event was captured for the purpose of the study.
VAE Algorithm Assessment for Occurrence of VAC
All patients were evaluated using the CDC VAE algorithm (Figure 3) and the
inclusion/exclusion criteria for the study. The first tier evaluated for VAC and documentation
was assessed for a two calendar day period of decreasing or stable respiratory mechanical
ventilator parameters (positive end expiratory pressure [PEEP] and fraction of inspired oxygen
[FiO2]), followed by a sustained increase in the same parameter (Appendix A). An occurrence of
VAC was noted with a sustained increase in the minimum PEEP by 3 cm H20 for > 2 calendar
days or a sustained increase in the minimum FiO2 by > 0.20 (20 points) for > 2 calendar days. In
addition, once a VAC was determined, patients were evaluated for occurrence of IVAC, possible
VAP, and probable VAP based on NHSN criteria.
Assessment for Predictor Occurrence
Each subject was assessed for the presence of four variables during the mechanical
ventilation period, 1) SSD-ETT, 2) sedation vacation, 3) alcohol withdrawal, and 4) history of
COPD (Appendix A).
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Presence of SSD-ETT
Although research indicates that that use of SSD-ETT prevents VAP, practice
modifications to all hospitals and populations lag due to an economic impact.9,16 At the study
site, the SSD-ETT was the only ETT available outside of the operating room (OR), and
anesthesia attempted to use the SSD-ETT on select surgical patients that were candidates for
post-operative ventilation. In addition, patients on mechanical ventilation were frequently
transferred to the VAHCS from other facilities that may not have implemented the SSD-ETT.
The type of ETT used during mechanical ventilation was recorded for each patient. The
presence of the SSD-ETT or not (standard ETT) was assessed and recorded once. Patients that
required re-intubation within 24 hours were noted in the comments if there were two different
types of ETT used for that ventilation period. Only one patient met this situation, and did not
meet criteria for VAE.
Daily Sedation Vacation
Documentation was reviewed for indication that sedation was lightened daily until the
patient was awakened, aroused, and had spontaneous ventilation.8,17 If any of the notes on each
calendar day indicated this occurrence, then a daily sedation vacation occurred. If there was an
overall 90% occurrence of a sedation vacation during the mechanical ventilation period, then a
positive occurrence was recorded.
Alcohol Withdrawal
Management of alcohol withdrawal in the ICU, especially the veteran population, is
challenging, and patients may require intubation and extended mechanical ventilation.18
Documentation was reviewed for occurrence of alcohol withdrawal during the mechanical
ventilation period. Alcohol withdrawal screening and management of symptoms of agitation
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were often reported using the Clinical Institute Withdrawal Assessment (CIWA) of Alcohol
Scale, yet did not necessarily indicate the diagnosis of alcohol withdrawal. A physician note was
required to indicate the presence of alcohol withdrawal for a positive occurrence during the
mechanical ventilation period.
History of COPD
Documentation of a history of COPD by a physician was acceptable as a positive history
of COPD. Since this was a retrospective study, COPD staging criteria (i.e. GOLD) was not
assessed.19 Therefore, if either the provider generated problem list or physician documentation
indicated the presence of COPD, then this was a positive occurrence. In addition, the known
COPD risk factor of cigarette smoking was collected for secondary analysis (history of smoking,
pack per year history, and current smoking history).
Secondary Outcome Data
Dates were de-identified during data collection and converted directly into numerical data
(i.e. days of care) for data entry and analysis. Secondary data included:
Mechanical ventilation days: number of days on the mechanical ventilator.
ICU days: number of patient days in the ICU for the mechanical ventilation event period.
Hospital days: total number of patient days in the hospital, inclusive of ICU days.
Mortality: did the patient expire during the hospitalization (yes or no).
Tracheostomy: days from intubation to tracheostomy (for mechanical ventilation event
period).
Study Endpoints
Endpoints of the mechanical ventilation period included: extubation >24 hours,
tracheostomy, discharge, or death. If a patient was extubated and re-intubated within 24 hours
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for any reason, it was documented in the comments, although time remained inclusive for the
mechanical ventilation period. Only the first mechanical ventilation episode per patient was
included in the study. Subsequent mechanical ventilation events on the same patient were not
assessed for VAE occurrence.
Data Analysis
Data analysis included the overall incidence rate of VAC and IVAC. Incidence rates
were calculated based on the number of events per 1000 ventilator days. Comparative data
between those with and without VAC were assessed with independent sample T-test or nonparametric equivalents, depending on whether data met assumptions for parametric statistics.
Logistic regression was performed on occurrence of VAC and four predictors (use of the SSDETT, daily sedation vacation, alcohol withdrawal, and history of COPD). Secondary outcomes
(mechanical ventilation days, ICU days, hospital days, and mortality) of veterans with VAC were
compared to veterans without VAC. The statistical testing was performed using IBM® SPSS®
Statistics 21, and a level of significance of 0.05 was set for all these tests.
Results
Sample
There were 280 subjects that met inclusion criteria. Using the CDC VAE algorithm, 20
patients met the VAC definition, resulting in a 24-month incidence of 7.38 per 1000 ventilator
days. Descriptive statistics are reported as a number (percentage) for categorical variables; and
as a mean value, standard deviation (SD), and 95% confidence interval (CI) for continuous
variables (Table 3). There were no statistically significant differences in demographics or
disease characteristics between the two groups (with VAC and without VAC).

34

Table 3: Sample Demographics and Characteristics of Patients With and Without VAC

Characteristic

Total Sample
(n=280)

Without VAC
(n=260)

With VAC
(n=20)

Sex, n (%)
Male
Female

272 (97.1)
8 (2.9)

253 (97.3)
7 (2.7)

19 (95.0)
1 (5.0)

Age, years, mean (SD)
Range

67.2 (10.4)
38-89

67.2 (10.5)

66.9 (9.4)

Race, n (%)
Black
White
Other

17 (6.1)
258 (92.1)
5 (1.8)

14 (5.4)
242 (93.1)
4 (1.5)

3 (15.0)
16 (80.0)
1 (5.0)

Ethnicity, n (%)
Hispanic
Not Hispanic
Unknown

3 (1.1)
254 (90.7)
23 (8.2)

2 (0.8)
235 (90.4)
23 (8.8)

1 (5.0)
19 (95.0)
0 (0.0)

28.4 (7.4)
(14.4-50.7)

28.5 (7.5)

27.0 (6.9)

16 (5.7)
88 (31.4)
71 (25.4)
80 (28.6)
25 (8.9)

15 (5.8)
78 (30.0)
69 (26.5)
75 (28.8)
23 (8.8)

1 (5.0)
10 (50.0)
2 (10.0)
5 (25.0)
2 (10.0)

ICU type, n (%)
MICU
SICU
ICU combination

141 (50.4)
119 (42.5)
20 (7.1)

129 (49.6)
111 (42.7)
20 (7.7)

12 (60.0)
8 (40.0)
0 (0.0)

ICU diagnosis, n (%)
Medical
Surgical
Respiratory Event
Charlson Score, mean (SD)
Range

71 (25.4)
73 (26.1)
136 (48.6)
5.8 (2.5)
0-13

67 (25.8)
69 (26.5)
124 (47.7)
5.8 (2.5)
0-13

4 (20.0)
4 (20.0)
12 (60.0)
5.8 (2.8)
0-12

Coronary Artery Disease, n (%)
Yes
No

262 (93.6)
18 (6.4)

243 (93.5)
17 (6.5)

19 (95.0)
1 (5.0)

Renal Disease, n (%)
Yes
No

123 (43.9)
157 (56.1)

116 (44.6)
144 (55.4)

7 (35.0)
13 (65.0)

BMI, mean (SD)
(Range)
BMI Groups:
BMI< 18.5
BMI 18.5-24.9
BMI 25-29.9
BMI 30-39.9
BMI >40

95% CI

ρ value*
.452

-5.060, 4.507

.909

.110

.086

-1.98, 4.81

.413ŧ

.341

.374

.569

-1.11, 1.18

.947ŧ

.787

.404
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Characteristic

Total Sample
(n=280)

Without VAC
(n=260)

With VAC
(n=20)

Diabetes Mellitus (DM), n (%)
Yes
No

118 (42.1)
162 (57.9)

113 (43.5)
147 (56.5)

5 (25.0)
15 (75.0)

Insulin-Dependent DM, n (%)
Yes
No

48 (17.1)
232 (82.9)

46 (17.7)
214 (82.3)

2 (10.0)
18 (90.0)

Liver Disease, n (%)
Yes
No

97 (34.6)
183 (65.4)

90 (34.6)
170 (65.4)

7 (35.0)
13 (65.0)

Cancer History, n (%)
Yes
No

80 (28.6)
200 (71.4)

76 (29.2)
184 (70.8)

4 (20.0)
16 (80.0)

Chronic Obstructive Pulmonary
Disease, n (%)
Yes
No
Smoking History, n (%)
Yes
No
Currently Smoking, n (%)
Yes
No
Pack per Year- mean (SD)
Range
Alcohol Abuse History, n (%)
Yes
No
Alcohol Withdrawal History, n
(%)
Yes
No

95% CI

ρ value*
.107

.543

.972

.379

.304
209 (74.6)
71 (25.4)

196 (75.4)
64 (24.6)

13 (65.0)
7 (35.0)

249 (88.9)
30 (10.7)

233 (90.0)
26 (10.0)

16 (80.0)
4 (20.0)

113 (40.4)
167 (59.6)

107 (41.2)
153 (58.8)

6 (30.0)
14 (70.0)

54.8 (31.6)
(n=185)
2-150

55.2 (32.0)
(n=171)

51.1 (26.1)
(n=14)

109 (38.9)
171 (61.1)

99 (38.1)
161 (61.9)

10 (50.0)
10 (50.0)

24 (8.6)
256 (91.4)

21 (8.1)
239 (91.9)

3 (15.0)
17 (85.0)

.248

.327
-13.35, 21.35

.649ŧ

.292

.395

*P value for Χ 2 or Fisher exact test.
ŧ
P value for Independent Sample T test

The majority of subjects were male (97.1%), Caucasian (92.1%), non-Hispanic (90.7%),
with a mean (SD) age of 67.2 (10.4) years. The majority of the ICU admission diagnoses were
related to a respiratory event (48.6%). The majority of these subjects had a history of smoking
(88.9%) with a mean 47.4 pack year history, and 40.4% reported they continued to smoke
36

tobacco. Although there was alcohol abuse history noted in 38.9% of the sample, only 8.6%
were previously diagnosed with alcohol withdrawal. No significant differences in demographic
or disease characteristics (Table 3) were found between the two groups (patients with and
without VAC). Categorical variables were analyzed by Χ2 test or Fisher exact test, and
independent sample T test was used for continuous variables.
Logistic regression was performed on occurrence of VAC and four predictors (use of the
SSD-ETT, daily sedation vacation, alcohol withdrawal, and history of COPD). A test of the full
model against the constant only model was not statistically significant (-2 Log likelihood
142.981, x2=1.118, p=.891). Variance accounted for in the model was estimated at 1%, and the
Hosmer and Lemeshow Test indicated the data were a good fit for the model (x2=3.781, df=4,
p=.437). Table 4 presents the regression coefficients (B), Wald statistics, odds ratio (OR), and
95% confidence intervals (CI). Results indicated that none of these four variables were
predictive of the occurrence of VAC.
Table 4: Logistic Regression (LR) Model Results
LR Model Predictors
Subglottic Secretion Drainage Endotracheal Tube
Sedation Vacation
Alcohol Withdrawal
Chronic Obstructive Pulmonary Disease

B

S.E.

-.205
-.007
-.101
.510

.652
.796
.781
.502

Wald

OR

.099
.000
.017
1.035

.815
.993
.904
1.666

95% CI
Lower Upper
.227
2.926
.209
4.725
.196
4.174
.623
4.454

ρ value
.753
.993
.897
.309

Outcome Data
During the 24 month period, 20 patients met the VAC definition (incidence of 7.38 per
1000 ventilator days). The VAC event etiology was diagnosed by the provider as pneumonia
(9), acute respiratory distress syndrome (5), pulmonary edema (2), pleural effusion (2),
atelectasis (1), and severe asthma (1). Using the VAE algorithm, eight of the 20 patients met the
IVAC definition (incidence of 2.95 per 1000 ventilator days), with four probable VAPs
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identified in this group. During the same time period, the infection preventionist reported a total
of 10 VAPs (incidence of 3.69 per 1000 ventilator days) to the VAHCS Infection Control
Committee.
The VAC group was associated with a significant longer duration of ICU stay, longer
mechanical ventilation period, more likely to have a tracheostomy during ICU stay, and higher
likelihood for mortality (Table 5). Although hospitalization stay was not found statistically
significant, patients that developed VAC had an average of 5 additional days in the hospital.
Table 5: Secondary Outcomes for Patients With and Without VAC
Outcome

Total Sample
(n=280)

Without VAC
(n=260)

With VAC
(n=20)

95% CI

ρ value*

Hospital LOS, mean (SD)
(range 2-94 days)

18.34 (16.13)
n=278
median=13.0

17.98 (16.27)
n=258

23.00 (13.62)

-12.38, 2.34

.180 ŧ

ICU LOS, mean (SD)
(range 2-73 days)

10.82 (11.53)
n=277
median=7

10.14 (11.19)
n=257

19.60 (12.58)

-14.62,-4.30

<.001ŧ

Ventilator Days, mean (SD)
(range 2-74)

5.66 (7.29)
median=3

5.01 (6.52)

14.05 (10.97)

-14.22, -3.85

.002 ŧ

Tracheostomy
Yes
No

19 (6.8)
261 (93.2)

13 (5.0)
247 (95.0)

6 (30.0)
14 (70.0)

48 (18.5)
212 (81.5)

11 (55.0)
9 (45.0)

.001

Mortality during
Hospitalization, n (%)
59 (21.1)
Yes
221 (78.9)
No
LOS, Length of Stay.
*P value for Χ 2 or Fisher exact test.
ŧ
P value for Independent Sample T test

.001

Discussion
Expanding surveillance to include VAE provides an improved surveillance tool that
rapidly and objectively identifies outcomes in mechanically-ventilated veterans. The new CDC
VAE protocol is easy to use with clear objective definitions.20 Identification of VAE with
specific definition criteria allows for the possibility of electronic extraction from the medical
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record, although rapid manual screening is a reality using a simple daily line listing (recording
the daily minimum FiO2 and PEEP).3 The VAE algorithm and protocol provides a reliable and
valid tool to identify VAC and IVAC, report and compare rates with confidence, and avoid prior
problems noted with the VAP definition.21 Questions regarding the VAE protocol specific to
NHSN reporting continue to be answered by CDC experts.
The sample population reflected the population at this VAHCS (97.1% male, 92.1%
Caucasian, 90.7% non-Hispanic, with average age of 67.2). A history of COPD was noted in
74.6% of the sample, with over 88.9% admitting to having a history of cigarette smoking, and
40.4% continuing to smoke. Therefore, it was not surprising that a respiratory event (48.6%) was
the reason for majority of the ICU admission diagnoses. The prevalence of COPD was expected
to be high in this population, and the odds ratio indicated that subjects with COPD were 1.67
times more likely to have a VAC. This is not unexpected and is supported by other studies that
demonstrate that COPD prolongs ventilator weaning thus increases the risk of complications.22,23
Data were not collected for polysubstance abuse, smoking crack cocaine, or smoking marijuana,
and was a limitation to the study.
The VAC incidence rate was 7.38 per 1000 ventilator days for a 24 month period. Data
were de-identified immediately; therefore, VAC rates by time periods cannot be obtained. VAC
event etiology was diagnosed by the provider as pneumonia (45%), acute respiratory distress
syndrome (25%), pulmonary edema (10%), pleural effusion (10%), atelectasis (5%), and severe
asthma (5%). This is comparable to a recent study that reported top VAC etiology as any
pulmonary complication (59%), pneumonia (23%), acute respiratory distress syndrome (16%),
pulmonary edema (18%), and atelectasis (11%).3 Historically during the same time period, the
infection preventionist reported a total of 10 cases of VAP (or an incidence of 3.69 per 1000
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ventilator days) to the VAHCS Infection Control Committee which is comparable to the IVAC
rate (incidence of 2.95 per 1000 ventilator days) in this study. The CDC VAE criteria for
possible VAP and probable VAP contain stricter criteria than the previous VAP definition, which
may account for only meeting criteria for four probable VAPs under the new algorithm. In
addition, the CDC VAE criteria excludes Candida species, coagulase-negative Staphylococcus
species, and Enterococcus species, when isolated from cultures of sputum, endotracheal
aspirates, bronchoalveolar lavage, and or protected specimen brushings which may account for
differences in case identification under the new criteria for possible VAP or probable VAP.20
Another area that impacts case identification is the mode of mechanical ventilation, and
this was found to be a limitation in this study. Medical management of patients on mechanical
ventilation includes various modes of ventilation that vary based on hospital and available
equipment. The major criteria for respiratory deterioration (VAC definition) include changes in
either FiO2 or PEEP, and CDC experts have excluded some modes of ventilation that specifically
impact the PEEP criteria (Table 6). For example, airway pressure release ventilation (APRV) is
a ventilation mode that the VAE protocol requires only FiO2 to be used for VAC surveillance,
where high-frequency ventilation and extracorporeal life support is excluded from surveillance.20
Table 6: Types of Mechanical Ventilation

Type of Mechanical Ventilation
Controlled Mandatory Ventilation (CMV)
Assist-Control Ventilation (ACV)
Synchronized Intermittent Mandatory Ventilation (SIMV)
Pressure Control Ventilation (PSV)
Pressure Support Ventilation (PSV)
Continuous Positive Airway Pressure (CPAP)
PCV+ without Inverse I:E Ratio (Dräger ventilators)
Pressure-Regulated Volume Control Ventilation (PRVC)
Volume Support Ventilation
Volume-Assured Pressure Support Ventilation
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Ventilator-Associated
Event (VAE)
Surveillance
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Type of Mechanical Ventilation
Adaptive Pressure Control Ventilation
Mandatory Minute Ventilation (MMV)
AutoFlow (Dräger ventilators)
Adaptive Pressure Ventilation (Hamilton GALILEO ventilators)
Volume Control Plus Ventilation (Puritan-Bennett ventilators)
Volume Targeted Pressure Control Ventilation
Pressure Controlled Volume Guarantee Ventilation (General Electric Ventilators)
Adaptive Support Ventilation
Proportional Assist Ventilation
Bi-Level Ventilation without Inverse I:E Ratio (Puritan-Bennett Ventilators)
Airway-Pressure Release Ventilation (APRV)
Pressure-Control Inverse Ratio Ventilation (PC-IRV)
Bi-Level Ventilation with Inverse I:E Ratio (Puritan-Bennett ventilators)
Bi-Vent Ventilation (Maquet SERVO-i ventilators)
PCV+ with Inverse I:E Ratio (Dräger ventilators)
DuoPAP Ventilation (Hamilton GALILEO ventilators)
Biphasic Intermittent Positive Airway Pressure Ventilation
Intermittent Mandatory Airway Pressure Release Ventilation

Ventilator-Associated
Event (VAE)
Surveillance
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)

Excluded from VAE Surveillance:
High Frequency Ventilation (HFV)
High Frequency Oscillatory Ventilation (HFOV)
High Frequency Jet Ventilation
High Frequency Percussive Ventilation
Volumetric Diffusive Ventilation (VDR, Percussionaire ventilators)
Extracorporeal Life Support (ECLS) with venous-venous cannulation
Extracorporeal Life Support (ECLS) with venous-arterial cannulation
Extracorporeal Membrane Oxygenation (ECMO)

No
No
No
No
No
No
No
No

*These types of mechanical ventilation are included in VAE surveillance, but oxygenation changes are assessed using fraction
of inspired oxygen (FiO2) data only during the period of time these types of mechanical ventilation are used. Positive End
Expiratory Pressure (PEEP) criteria are not used to assess for VAEs when receiving one of these types of mechanical
ventilation.

At the study site, the option of Bi-Level Ventilation was recorded for numerous patients
and some patients frequently switched from one mode of ventilation to Bi-Level Ventilation and
back again; therefore, only the FiO2 criteria was followed most of the time in many patients.
This ventilation exclusion may have limited the identification of VAC cases in the study
population. CDC experts are now prospectively asking participating National Healthcare Safety
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Network hospitals to submit the mode of ventilation (APRV) to determine the impact of these
alternate modes on the VAE algorithm and rates.20
This study reported a VAC incidence of 7.38 per 1000 ventilator days (or 7.1%) with
study endpoints that may have impacted the lower rate (tracheostomy and first extubation).
These study endpoints were necessary to evaluate the impact of the SSD-ETT on the occurrence
of VAC. This study VAC rate was lower than a recent retrospective study of 600 mechanically
ventilated patients with an overall VAC incidence of 21.2 per 1000 ventilator days (or 23%).3
However, these patients had a longer duration of ventilation (14.7 days [CI 13.2-16.4]), with an
average of 8% VAC rate among ventilated patients less than 7 days, and an average of 37% for
patients ventilated more than 7 days.3
Although these data were not collected for this study due to the study endpoints of
tracheostomy, 80% of VACs occurred within the first seven days on mechanical ventilation.
This study was a single setting confined to all 280 patients in a 24 month period compared to a
multi-site setting of 600 patients (three hospitals in which each site randomly selected 100
patients ventilated 2-7 days and 100 patients ventilated more than seven days).3 In addition, the
occurrence of VAC was defined slightly different (sustained increase in the minimum PEEP by
2.5 cm H20 for > 2 calendar days or a sustained increase in the minimum FiO2 by >15 points for
> 2 calendar days) than this study, which may account for additional cases meeting criteria.
Under the new CDC VAE protocol, patients may have more than one VAE event during a
ventilation period (must have 14 days between a VAE event); and in addition to the respiratory
deterioration criteria, specific infection criteria for IVAC, possible VAP, and probable VAP are
included.20 Therefore, the VAC incidence rate of this study is limited to the population and
available data, and lack generalizability.
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Other important limitations include the retrospective nature of the study, and limitation of
the nature of the veteran population served at the VAHCS. The study sample was predominantly Caucasian, non-Hispanic male veterans with complex medical morbidities. There
were no significant differences in demographics or acuity score (Charlson score) between
patients with and without VAC, and morbidities were expected in this veteran population.
The four predictors (SSD-ETT, sedation vacation, alcohol withdrawal, and history of
COPD) were not found significant in this study. Although 17.1% of veterans did not have a
SSD-ETT in place, the SSD-ETT was in place majority of time (82.9%), and there was no
significant difference between groups (patients with VAC had a SSD-ETT 85.0% compared to
82.7% of patients without VAC). This finding was unexpected since the SSD-ETT is associated
with a reduction in VAP. 9,10 One reason may be that VAE identifies many different events in
addition to VAP. A limitation to this study is that documentation of the function of the SSDETT was not collected. Amount of intermittent or continuous suction based on manufacturer
recommendations were not routinely documented, only that the SSD-ETT was in place.
Previous research indicated that endotracheal tube-suction lumen dysfunction occurred in 48% of
the participants.24
There was a high prevalence of COPD in this population (74.6%), and no significant
difference between the group with VAC and the group without VAC. The odds ratio with VAC
was 1.666 but not statistically significant, although this is clinically important and a larger
sample size is needed to detect statistical difference. Data were not collected on the type of
ventilation (e.g. APRV), and whether only the FiO2 criteria was used for assessment of a VAE
event. Different ventilation modes may be used for treatment of respiratory events and COPD,
and may have been impacted by the VAE protocol.20
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The provider, nurse, and respiratory therapy notes were reviewed for documentation of a
daily sedation vacation when on mechanical ventilation. An overall positive sedation vacation
occurred if there was at least 90% daily sedation vacation documented, so the rate may be
impacted by the number of mechanical ventilation days. In addition, a documentation template
that indicated that nursing and respiratory therapy collaborated on weaning, spontaneous
breathing trial, and the occurrence of a sedation vacation was implemented in 2010, and used by
nursing. The overall sedation vacation rate indicated a successful IHI VAP prevention strategy
at 91.1%.25
Although alcohol abuse history was documented in 38.9% of the veterans, polysubstance
abuse history was not collected and maybe a limitation to the study. The CIWA scale was used
by nurses to document the effects of alcohol withdrawal, and was used whenever there was a
physician order (preventative assessment based on prior history or admission of a high alcohol
intake).18 Although the CIWA scale was used in some patients indicating agitation, there was no
physician documentation of alcohol withdrawal, which may have impacted the results. This
study used physician documentation of alcohol withdrawal as a positive occurrence during
mechanical ventilation, with 8.9% of the sample experiencing alcohol withdrawal (group with
VAC had 10% with alcohol withdrawal, and group without VAC had 8.8% with alcohol
withdrawal). It was noted that several patients were electively intubated and mechanically
ventilated to protect the airway at the start of alcohol withdrawal. The timing and effect of this
preemptive strategy to prevent complications was not studied. Although only the occurrence of
alcohol withdrawal was collected for this study, in reviewing the documentation the patients
differed in when symptoms of agitation developed and the level of sedation needed. Thus, this
study did not measure the impact of alcohol withdrawal and when it occurred during mechanical
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ventilation, nor did it measure the intensity of alcohol withdrawal and the necessary sedation.
Individual experiences, early identification, and treatment of alcohol withdrawal were not
collected and may impact occurrence of VAC.
This study supported earlier research that VAC was associated with increased mechanical
ventilator days of care, increased hospital length of stay, and increased mortality.3,4 In addition,
this study found that patients with VAC were more likely to get a tracheostomy, suggesting
further that the VAC criteria are a better indicator for patient outcomes.
There is a large gap in research, across adult mechanically-ventilated populations, with
the development of a new VAE protocol. Respiratory deterioration criteria (sustained increase in
FiO2 or PEEP) have emerged as a better indicator of mortality and other patient outcomes, and
research is just beginning. Research is needed to determine the impact of the IHI VAP strategies
(individually and as a bundle) on the incidence of VAC, and the true economic impact of VAC.
New products have flooded the market to prevent VAP, but the impact of VAC is unknown.
Implications for Practice and Research
The incidence of VAP has been used as the outcome measurement for components of the
IHI ventilator bundle in numerous studies.2,8,26 Research is needed to determine the effect of the
ventilator bundle on the incidence of VAC in different adult populations. This study is the first
known attempt to look at the impact of VAP prevention strategies (use of the SSD-ETT and
sedation vacation) on the outcome of VAC in veterans. Study results indicate that compliance to
these prevention practices were widely used (SSD-ETT 82.9% and sedation vacation 91.1%).
Electronic documentation for sedation vacation varied, although most notes involved used a
template to satisfy this strategy. High compliance to use of the SSD-ETT was expected, as it is
the only option available to use throughout the study site except the OR. This resulted in 50% of
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subjects that lacked an SSD-ETT came from the OR, and 50% were transferred from outside
hospitals or intubated in-route by emergency medical staff. Consideration to expand the routine
use of a SSD-ETT to the OR would be expensive and was not supported with results from this
study, although expanding to select surgical patients maybe a better strategy.
Ventilator management strategies may influence VAC incidence rates. Although CDC
experts have managed to provide an objective definition, there may still be some variability and
confusion understanding ventilator parameters. The novice infection preventionist will need to
develop a collaborative relationship with respiratory therapists and other critical care staff to
facilitate collecting and understanding these data elements. The VAE algorithm is recommended
as a surveillance tool in adults, and the occurrence of VAC may be infectious or non-infectious
in nature. This expands the role of the infection preventionist, as identification and further
analysis of VAC etiology may uncover preventable root causes that results in practices changes
outside of infection prevention and control.
Future research in identifying predictors of VAC is needed to guide multidisciplinary
interventions or changes in the IHI ventilator bundle. This study provides a baseline VAC
incidence rate in a veteran population, and supports other research that ICU length of stay, time
on mechanical ventilation, and hospital mortality increases with ventilator-associated
complications.2-4,27
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CHAPTER 4: PREVENTION STRATEGIES IMPACTED BY VAE SURVEILLANCE
Summary Abstract
The Center for Disease Control and Prevention (CDC) recently expanded infection
control surveillance definitions to include all ventilator-associated events (VAE).1 The VAE
algorithm identifies ventilator-associated conditions (VAC) based on respiratory deterioration
criteria, and replaces the controversial ventilator-associated pneumonia (VAP) definition.2,3 In a
recent retrospective study, VAC incidence was described and four predictors explored. During
data collection for this study, a few challenges were faced when extracting variables from the
electronic medical record (EMR). These variables (mechanical ventilation parameters, sedation
vacation, and subglottic secretion-drainage endotracheal tube [SSD-ETT]) will be discussed and
how they impact recommended infection prevention strategies.4,5
Mechanical Ventilation
Medical treatment of critically-ill patients may require the assistance of an artificial
airway (endotracheal tube [ETT]) and mechanical ventilation to sustain life during a critical
illness or acute injury. A mechanical ventilator is a device that is able to assist or control patient
respirations in a continuous manner through the ETT. The infection preventionist (IP)
collaborates with the critical care multidisciplinary team to minimize the risk of ventilatorassociated infections and decrease mechanical ventilation days.6,7
Patients are routinely monitored for gas exchange, and the work of breathing (WOB) is
an indicator of the workload of the respiratory muscles.8 This respiratory measurement is a key
index that is used during evaluation of respiratory effort, and is actually measured as the
transpulmonary pressure change that is necessary to surpass the elastic and resistive components
times the volume of air that is moved into and out of the lung. The mechanical ventilator
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supplements or performs the WOB during inspiration, while expiration remains passive. During
mechanical ventilation, the WOB is reduced when there is synchrony between patient and
ventilator, thus creating smooth interaction between the patient’s respiratory muscles and the
assisted ventilation.9,10 By reducing the WOB, ventilated patients, or patients with impending
respiratory failure, can decrease respiratory muscle demands, conserve energy, and improve
respiratory parameters; and successfully wean from mechanical ventilation prior to developing
complications associated with being on a ventilator.9
Imposed resistive WOB includes the inspiratory resistance that occurs from addition of
the ETT and ventilator circuit to the usual pathway of the patient’s airway and respiratory tract.
Imposed resistive WOB varies between patients and includes: inspiratory flow rate demand, ETT
resistance (based on cross-sectional area, secretion and biofilm occurrence), breathing circuit
resistance (diameter, humidifier), and ventilator resistance (trigger sensitivity setting, response
time). Although mechanical ventilation is medically required to ease the WOB, it can increase
WOB and stimulate episodes of patient-ventilator asynchrony, thus delay weaning and put
patients at risk for ventilator-associated complications.11,12
Recommended strategies to prevent VAP include: conduct active surveillance for VAP,
perform daily readiness to wean and use weaning protocols, prevent aspiration, and minimize
colonization of equipment.4 Recently, the CDC updated and expanded the surveillance
definition of VAP to include all VAE.
Mechanical Ventilation and VAE
Changes in mechanical ventilator parameters frequently occur for various reasons to
manage and wean the critically-ill patient. There are different ventilation modes aimed at
minimizing these problems, promoting spontaneous ventilation, and improving patient outcomes;
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or these changes may inadvertently increase imposed resistive WOB and patient-ventilator
asynchrony.13-15 The VAE surveillance definition uses the ventilator parameters of the daily
minimum fraction of inspired oxygen (FiO2) or the positive-end expiratory pressure (PEEP) as
indicators of stability on the ventilator, and as markers of respiratory deterioration for VAC
(Figure 4).1

Figure 4: VAE Surveillance Algorithm; from: http://www.cdc.gov/nhsn/acute-care-hospital/vae/
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Although treatment of oxygen desaturation and respiratory failure may require sustained
increase in FiO2, the treatment of airflow obstruction frequently requires PEEP to be added to
ventilator settings.16 There are several modes of mechanical ventilation possible to use to
facilitate ventilation.
The CDC VAE protocol excludes some ventilation delivery modes (Table 7); and in
other modes, such as airway pressure release ventilation (APRV), requires only the assessment
of FiO2 as an indicator of stability or respiratory deterioration.1 Thus, some modes of ventilation
limits VAE assessment to only use the FiO2 as the respiratory deterioration indicator, and the
significance of this exclusion is not known.1
Table 7: Types of Mechanical Ventilation
Type of Mechanical Ventilation
Controlled Mandatory Ventilation (CMV)
Assist-Control Ventilation (ACV)
Synchronized Intermittent Mandatory Ventilation (SIMV)
Pressure Control Ventilation (PSV)
Pressure Support Ventilation (PSV)
Continuous Positive Airway Pressure (CPAP)
PCV+ without Inverse I:E Ratio (Dräger ventilators)
Pressure-Regulated Volume Control Ventilation (PRVC)
Volume Support Ventilation
Volume-Assured Pressure Support Ventilation
Adaptive Pressure Control Ventilation
Mandatory Minute Ventilation (MMV)
AutoFlow (Dräger ventilators)
Adaptive Pressure Ventilation (Hamilton GALILEO ventilators)
Volume Control Plus Ventilation (Puritan-Bennett ventilators)
Volume Targeted Pressure Control Ventilation
Pressure Controlled Volume Guarantee Ventilation (General Electric Ventilators)
Adaptive Support Ventilation
Proportional Assist Ventilation
Bi-Level Ventilation without Inverse I:E Ratio (Puritan-Bennett Ventilators)
Only FiO2 is assessed, when used:
Airway-Pressure Release Ventilation (APRV)
Pressure-Control Inverse Ratio Ventilation (PC-IRV)
Bi-Level Ventilation with Inverse I:E Ratio (Puritan-Bennett ventilators)
Bi-Vent Ventilation (Maquet SERVO-i ventilators)
PCV+ with Inverse I:E Ratio (Dräger ventilators)
DuoPAP Ventilation (Hamilton GALILEO ventilators)
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Ventilator-Associated
Event (VAE)
Surveillance
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)
Yes* (FiO2 only)

Type of Mechanical Ventilation
Biphasic Intermittent Positive Airway Pressure Ventilation
Intermittent Mandatory Airway Pressure Release Ventilation

Ventilator-Associated
Event (VAE)
Surveillance
Yes* (FiO2 only)
Yes* (FiO2 only)

Excluded from VAE Surveillance:
High Frequency Ventilation (HFV)
No
High Frequency Oscillatory Ventilation (HFOV)
No
High Frequency Jet Ventilation
No
High Frequency Percussive Ventilation
No
VolumetricDiffusive Ventilation (VDR, Percussionaire ventilators)
No
Extracorporeal Life Support (ECLS) with venous-venous cannulation
No
Extracorporeal Life Support (ECLS) with venous-arterial cannulation
No
Extracorporeal Membrane Oxygenation (ECMO)
No
*These types of mechanical ventilation are included in VAE surveillance, but oxygenation changes are assessed using fraction
of inspired oxygen (FiO2) data only during the period of time these types of mechanical ventilation are used. Positive End
Expiratory Pressure (PEEP) criteria are not used to assess for VAEs when receiving one of these types of mechanical
ventilation.

The VAE algorithm uses at least a two calendar day of stable or improving FiO2 or PEEP
values as an indicator of patient stability or improvement. Following this, an occurrence of VAC
is based on a two calendar day of worsening oxygenation indicated by specific changes in FiO2
or PEEP (Figure 4). If APRV or similar mode is used, then only the FiO2 is assessed during
VAE surveillance for stability and changes, so any changes in levels of airway pressure or PEEP
(high or low) to treat the patient’s condition are not assessed as a predictor of change.14,17 These
alternative ventilation modes, such as APRV, may be used to treat respiratory failure, improve
oxygenation, and minimize patient-ventilator asynchrony.17 Thus while promoting spontaneous
ventilation and maintaining FiO2 levels, adjustments are usually necessary in the positive
pressure (divided into two time periods: high airway pressure and low airway pressure) and auto
PEEP (result of a short release time between pressures resulting in residual volume).14,17
Compared to conventional modes, APRV may be used to improve alveolar recruitment in
hypoxemic respiratory failure, maintain intrinsic PEEP, and increase pulmonary blood flow,
while enabling spontaneous ventilation.
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It was noted during data collection for clinical research, that some patients were switched
from a conventional mechanical ventilation mode with traditional PEEP to a Bi-Level mode,
which is an excluded ventilation mode and requires only assessment of the FiO2 for VAE (Table
7).1 Reviewing electronic documentation indicated that these patients were able to maintain
oxygenation during BiLevel ventilation mode; thus, the FiO2 criterion was not met for a VAC,
but physician diagnosis indicated treatment of a VAC in a few cases. This change in ventilation
mode may exclude VAE cases with the current algorithm, and could be one explanation of the
lower VAC incidence (7.4 per 1000 ventilator days) found in the study, compared to a previous
study (21.2 per 1000 ventilator days).18
Challenges with VAE Criteria
The VAE algorithm includes objective criteria for VAC (with specific measurements for
FiO2 or PEEP), criteria for infection-related ventilator-associated condition (with specific
measurements of white blood cell count or fever, and start of new antimicrobial therapy), and
specific microbiologic criteria to quantify purulent sputum and cultures.1 Although the VAE
protocol is an improvement to the VAP definition, there are still potential problems with the
definition. For example, during mechanical ventilation the FiO2 and PEEP settings may
temporarily change during weaning, thus creating a minimum value that is not reflective of the
true clinical picture. In another example, clinicians may temporarily adjust the PEEP to zero
during spontaneous breathing trials (SBT), and then the patient is placed back to a particular preSBT level. In this case, the patient will always have a zero recorded for a minimum PEEP value.
Unfortunately, there is still opportunity to manipulate the VAE rate, as there was with
VAP rates.2 For example, since there is no minimum time period required to be counted as the
minimum daily value for FiO2 or PEEP, ventilator settings can be purposely lowered in an
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attempt to minimize VAC rates. In addition, if the criteria are extracted from the EMR, the IP
may never realize the patient is only temporarily on the settings for weaning. During data
collection, these potential problems were not encountered since the data was retrospectively
collected, but some patients had several ventilation changes during the course of treatment.
During the assessment of infection-related ventilator-associated condition (IVAC)
criteria, in addition to white blood cell count or fever, the evaluation of whether a new
antimicrobial agent meets the definition criteria may be somewhat complex.1 The IVAC criteria
were not intended only to assess for VAP, but for other infectious processes, and the
antimicrobial list is reflective of this and may be confusing to some IP.18 Specific criteria
includes timing of starting the antimicrobial agent two days before or after the day of VAC
event, verifying that the antimicrobial agent is eligible for inclusion, and verifying four
consecutive qualifying antimicrobial days (QAD). Challenges include addressing acceptable
variations in the QAD when the patient has renal insufficiency or renal failure, and addressing
antibiotic changes during the four consecutive QAD.1 During data collection, there usually were
no problems meeting the QAD when the antibiotic was started within the five day window,
although incomplete QAD occurred when the patient was transferred to hospice or expired.
Assessment of possible VAP and probable VAP include specific microbiologic criteria,
and explanations of the variations that may be reported and encountered in practice.1 Not all
healthcare facilities are able to process respiratory specimens the same, and the intent of the
VAE algorithm is to provide measurable objective criteria.18,19 Thus, purulent sputum is defined
quantitatively in an attempt to ensure validity. Some laboratories may need to change their
methods or reporting practices to ensure that the results are easily interpreted for VAE criteria.
In addition, normal oral flora and common oral pathogens (e.g. Candida, enterococcus) are
57

excluded from the probable VAP definition.1 For example, during data collection even though
gram stain met criteria, any sputum culture of Candida was not assessed for VAP.
IHI Ventilator Bundle and Sedation
National quality improvement initiatives in critical care units include the Institute for
Healthcare Improvement (IHI) ventilator bundle.6 Although this bundle is not inclusive of all
possible preventative strategies for mechanically-ventilated patients, these evidence-based
practices have become an intensive care unit (ICU) standard of care. When implemented as a
bundle, these interventions have better patient outcomes than single interventions; thus ventilator
bundle checklists have been adopted in the ICU and daily adherence is frequently monitored on
multidisciplinary daily rounds.20 Compliance is achieved when all five elements are met
(elevation of the head of the bed 30°, peptic ulcer disease prophylaxis, deep venous thrombosis
prophylaxis, chlorhexidine daily oral care, and daily sedation vacation and assessment of
readiness to extubate).6
A significant component of the IHI ventilator prevention bundle is the sedation vacation
and assessment of readiness to extubate.6 Sedation is used to reduce pain, agitation, anxiety,
maintain patient-ventilator synchrony, and reduce WOB; and can be given as a continuous
infusion or intermittent dose, with attention to dosing to avoid possible metabolite accumulation
and over sedation.9,21,22 Combinations of barbiturates, sedatives, analgesics, and/or
neuromuscular agents are used to decrease pain and agitation, and reduce oxygen consumption
during mechanical ventilation, resulting in limiting the patient’s communication so dosing is
often at the nurses’ discretion or based on a sedation scale.23
Documentation of the patient’s sedation level may be based on an ICU sedation protocol
and scale, or subjective documentation that evaluates levels of sedation. It is recommended that
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sedation is lightened daily until the patient is awakened and aroused, and during this time
patients are assessed neurologically for readiness to extubate.24 Sedation interruption with a
spontaneous breathing trial has been found to decrease ventilator days; and the use of sedation
protocols in addition to spontaneous breathing trials to manage ventilator patients is
recommended.22,25,26 Although complete success of this intervention occurs when the patient’s
sedation level is lightened enough for spontaneous ventilation to occur; this maneuver is not
without risk of self extubation, desaturation, and patient-ventilator asynchrony.24 Daily
interruption of sedation and spontaneous breathing trials are not done automatically and
irrespective of clinical state, but in collaboration with the multidisciplinary team. 24,25,27
Compliance to this IHI ventilator bundle component may be achieved when the team only
discusses the overall weaning interventions, since the performance of a sedation vacation or
spontaneous breathing trials may be contraindicative.26,28,29
During data collection for the retrospective study of 280 mechanically ventilated
patients, it was noted that nursing ICU notes included templates for documentation of the IHI
ventilator bundle components in the EMR. It was difficult to ascertain whether a sedation
vacation was undertaken or if it was only discussed based on documentation, since a general
template note was used to meet the compliance intent of the bundle. For example, the ICU
nursing template referred to collaborating with respiratory therapy to “assess for readiness to
wean and sedation vacation”, this was done daily in addition to a nursing sedation scale note
each shift. In general, the respiratory therapist documented ventilator changes on a flow sheet
and provided one general note per shift, but there was no indication when a “sedation vacation”
was occurring based on ventilator changes. On occasion, the ICU nurse would expand from the
template and provide further details regarding the sedation vacation and whether it was
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contraindicated, but this was not consistent. Daily multidisciplinary team rounds are conducted
in the ICU, and the IHI ventilator bundle components are discussed, although retrospectively
interpreting whether the patient had a sedation vacation from the EMR was difficult due to the
electronic template in use at the time. Improvements to the electronic template to include
mandatory components to assess and follow-up whether the sedation vacation was successful or
contraindicated would improve the documentation of this compliance measure.
Subglottic Secretion Drainage-Endotracheal Tube (SSD-ETT)
During mechanical ventilation, the ETT creates a conduit for bacteria in and around the
tube to migrate down the respiratory tract and put the patient at risk for respiratory infections.30
Recent innovations in the cuff and tube design of the ETT are aimed at decreasing
microaspiration of oral/pharyngeal secretions.31-33 Recommended strategies to prevent aspiration
include the use of subglottic suction and to maintain 20 cm H2O cuff pressure.4,33,34
The purpose of the SSD-ETT is to remove subglottic secretions that pool above the ETT
cuff, and maintain continuous or intermittent suction. Although healthcare facilities have
implemented the SSD-ETT, all populations may not be included (e.g. operating room) and there
are no guidelines to monitor compliance. In a recent study, malfunction of the subglottic suction
port was reported at 48%, and subglottic suction may predispose or cause tracheal injury.31,35
During review of 280 mechanically-ventilated patients EMR in a recent study, no documentation
on the function of the SSD-ETT was found, only that the patient had a SSD-ETT placed. In
addition, when patients are transferred from another facility, or intubated during emergency
management service, there were no procedure noted that changed the ETT to a SSD-ETT, and
there are no recommended guidelines.

60

The SSD-ETT is used as a VAP prevention strategy, and documentation of appropriate
function should be standard to ensure effectiveness of the SSD-ETT. In addition, if a facility has
implemented the SSD-ETT but excluded some populations, it would be prudent to do a risk
assessment and assess infection risk.5 Based on the infection control risk assessment, changes in
practice and procedure should be implemented to ensure that patients requiring longer periods of
mechanical ventilation are given the same VAP prevention measures.4,33
Implications
Strategies to prevent VAP include VAP surveillance, although now surveillance has
expanded to include all VAE and problems with the definition may not capture all cases.
Experts at CDC are aware of the potential problem with the VAE criteria, and want CDC
National Healthcare Safety Network (NHSN) users to provide prospective data on the use of
APRV and alternative modes of ventilation impacted by exclusion of PEEP.1 In the meantime,
hopefully the algorithm does not promote an inconsistent reporting of VAC incidence based on
these ventilator parameters (FiO2 and PEEP), or provide a way to decrease reported VAC
incidence.2 In addition, the IP will need to review the new antimicrobial and microbiological
criteria, and implement any necessary changes the CDC makes in the future. Regardless, this
algorithm is an improvement over the subjective VAP definition, and provides the IP the
opportunity to identify and analyze the incidence of infectious and non-infectious ventilatorassociated complications.18
Although literature supports the success of the ventilator prevention bundle, the level of
compliance may impact achievable outcomes, and further research on the impact of evidencebased bundles on the incidence of VAC is needed.20,28,36,37 Daily sedation vacation or sedation
interruption, along with assessment for readiness to wean, and spontaneous breathing trial, are
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grouped together as one bundle component but each component should be addressed separately.
This research study noted a possible disparity in the use of a template for EMR documentation of
a “discussion” of a sedative interruption with whether there was an actual performance of a
sedation vacation.
National guidelines recommend the use of SSD-ETT to prevent aspiration, thus reducing
VAP, although specific populations are not addressed and the standard ETT is still available for
use.4 Universal implementation would be costly, for example, every patient having a surgical
procedure with general anesthesia does not necessarily need a SSD-ETT.38 Concerns over
improper use of the SSD-ETT, and the necessity to follow manufacturer’s recommendations for
safety, prompt the recommendation to document use of the SSD-ETT, monitor and document
compliance to suction, and document function.
Challenges in ICU nursing electronic documentation include the inclusion of various
nursing standards, patient education, performance measures, and compliance to IHI bundle
interventions. Collaboration is needed between ICU nursing and respiratory therapy to ensure
that the required documentation for ventilator bundle, SSD-ETT management, and other
ventilator management and weaning documentation is achieved. Further clarification and
education of staff on the IHI ventilator bundle, sedation vacation and weaning components,
maintenance of the SSD-ETT, electronic documentation and use of templates, and impact on
outcomes is necessary to ensure success of infection prevention strategies. The CDC continues
to refine and clarify the VAE algorithm, and those conducting surveillance need to identify
issues and report concerns. Changes in monitoring practices may be necessary, and flexibility is
important as the new VAE definition evolves.
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APPENDIX A: DATA COLLECTION TOOLS
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Data Collection: Study Variables
ventilator)

Participant #
DOB
Age
Gender
Height
Weight
BMI
Race
Ethnicity
Marital status
Coronary Artery Disease Hx
Rheum Hx
Liver Disease Hx
Diabetes Mellitus (DM) Hx
Insulin Dependent DM Hx
Renal Disease Hx
Cancer HX
Chronic Obstructive Pulmonary Disease
HX
Smoking Hx
Pack per Year
Currently Smoking
Alcohol Abuse HX
Alcohol Withdrawal Hx
Charlson Score
Admission Diagnosis
Admission Ward
Expired?
Hospital LOS (number of days from hospital admission

Vent Days (number of days on ventilator)
Where intubated
ETT type
SSD-ETT
Surgery (number of days from surgery to ETT)
Surgery Type
Tracheostomy?
ETT to Trach Days
(number of days from intubation to trach)

Stable on Vent > 2D
Stable on Vent > 3D
T>38 or<36?
WBC>12000 or <4000?
New Antimicrobial and continues >4D
Purulent Secretions >25 neutrophils
Organism
Culture Source
Culture Comments
SSD-ETT?
Daily Sedation Vacation?
Alcohol Withdrawal?
COPD?
VAC event?
Days from Vent Start to VAC
Type of VAC event
VAE event?
Days from Vent Start to VAE
IVAC event?
Days from Vent Start to IVAC
Possible VAP event?
Probable VAP event?
Comments

date to hospital discharge date)

ICU Diagnosis
ICU type
ICU LOS (number of days from ICU admission date to ICU
discharge date)

Intubation to Vent (number of days from intubation to
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CDC Surveillance for Ventilator-Associated Events (VAE) in Adults
Surveillance Definitions for VAE:
•For use in acute and long-term acute care hospitals and inpatient rehabilitation facilities.
•For use in patients ≥ 18 years of age who are on mechanical ventilation for ≥3 calendar days.
•NOTE: patients on rescue mechanical ventilation (e.g., HFV, ECMO, mechanical ventilation in prone position) are EXCLUDED.

Patient has a baseline period of stability or improvement on the ventilator, defined by ≥ 2 calendar days of stable
or decreasing FiO2 or PEEP. Baseline FiO2 and PEEP are defined by the minimum daily FiO2 or PEEP measurement
during the period of stability or improvement.
After a period of stability or improvement on the ventilator, the patient has at least one of the following
indicators of worsening oxygenation:
1) Minimum daily FiO2 values increase ≥ 0.20 (20 points) over baseline and remain at or above that increased level for ≥
2 calendar days.
2) Minimum daily PEEP values increase ≥ 3 cmH2O over baseline and remain at or above that increased level for ≥ 2
calendar days.

Ventilator-Associated Condition (VAC)
On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of
worsening oxygenation, the patient meets both of the following criteria:
1) Temperature > 38 °C or < 36°C, OR white blood cell count ≥ 12,000 cells/mm3 or ≤ 4,000 cells/mm3.
AND
2) A new antimicrobial agent(s) is started, and is continued for ≥ 4 calendar days.

Infection-related Ventilator-Associated Complication (IVAC)
On or after calendar day 3 of mechanical ventilation
and within 2 calendar days before or after the onset
of worsening oxygenation, ONE of the following
criteria is met:
1) Purulent respiratory secretions (from one or more
specimen collections)
•Defined as secretions from the lungs, bronchi, or
trachea that contain >25 neutrophils and <10 squamous
epithelial cells per low power field [lpf, x100].
•If the laboratory reports semi-quantitative results, those
results must be equivalent to the above quantitative
thresholds.
2) Positive culture (qualitative, semi-quantitative or
quantitative) of sputum*, endotracheal aspirate*,
bronchoalveolar lavage*, lung tissue, or protected
specimen brushing*
*Excludes the following:
• Normal respiratory/oral flora,
mixed respiratory/oral flora or
equivalent
• Candida species or yeast not otherwise specified
• Coagulase-negative Staphylococcus species
• Enterococcus species

On or after calendar day 3 of mechanical ventilation and
within 2 calendar days before or after the onset of
worsening oxygenation, ONE of the following criteria is
met:
1) Purulent respiratory secretions (from one or more
specimen collections—and defined as for possible VAP)
AND one of the following:
•Positive culture of endotracheal aspirate, ≥ 105 CFU/ml or
equivalent semi-quantitative result
•Positive culture of bronchoalveolar lavage, ≥ 104 CFU/ml or
equivalent semi-quantitative result
•Positive culture of lung tissue, ≥ 104 CFU/ml or equivalent
semi-quantitative result
•Positive culture of protected specimen brush, ≥ 103 CFU/ml
or equivalent semi-quantitative result
2) One of the following (without requirement for purulent
respiratory secretions):
•Positive pleural fluid culture (where specimen was obtained
during thoracentesis or initial placement of chest tube and
NOT from an indwelling chest tube)
•Positive lung histopathology
•Positive diagnostic test for Legionella spp.
•Positive diagnostic test on respiratory secretions for
influenza virus, respiratory syncytial virus, adenovirus,
parainfluenza virus

Probable Ventilator-Associated Pneumonia
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Possible Ventilator-Associated Pneumonia

Data Collection: VAE Parameters
Mechanical
Ventilation
Day#
1

Minimum
PEEP

Minimum
FiO2

Minimum
Temperature

Subject#______________________
Maximum
Temperature

Minimum
WBC

Maximum
WBC

Antibiotic

Specimen
Type

Gram
Stain
(Poly/Epis)

Organism

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Minimum PEEP= daily minimum positive-end expiratory pressure (PEEP); Minimum FiO2= daily minimum fraction inspired oxygen (FiO2); WBC=white
blood cell count; antibiotic=antimicrobial agents; polys/epis=polymorphonuclear leukocytes and squamous epithelial cells
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Data Collection: Assessment of Predictors
SUBJECT#_______________________
Mechanical
Ventilation Day#

SSD-ETT* (Y/N)

Daily Sedation
Vacation (Y/N)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

*Positive occurrence only needs to be documented once
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Alcohol
Withdrawal*
(Y/N)

COPD
History*
(Y/N)

APPENDIX B: BAY PINES VAHCS IRB APPROVAL
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APPENDIX C: UNIVERSITY OF CENTRAL FLORIDA IRB APPROVAL
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APPENDIX D: CITI TRAINING
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